Molecular simulation emerges as most viable near-term quantum computing application
Updated
Updated · The Quantum Insider · May 4
Molecular simulation emerges as most viable near-term quantum computing application
14 articles · Updated · The Quantum Insider · May 4
Across eight assessed use cases, the report says drug discovery, Materials science and catalyst design are the clearest candidates, with practical deployment broadly estimated in five to 10 years.
It says current machines remain too error-prone and small for commercial value, while optimization, AI and climate modeling face longer timelines and less certain advantage over strong classical systems.
Cryptography sits between those groups: breaking modern encryption is still seen as 10 to 20 years away, but post-quantum defences are already being standardized and deployed.
Quantum computing promises revolutionary drugs, but is it a sound investment when classical AI is advancing even faster?
With new research threatening Bitcoin's encryption, is the global race against quantum code-breakers a sprint we are already losing?
As some banks curb quantum research, early wins in logistics are clear. Where does the real commercial advantage lie today?
Overcoming Hardware Barriers: The Road to Practical Quantum Molecular Simulation by 2030
Overview
Between 2025 and 2026, major breakthroughs in hybrid quantum-classical algorithms, such as IBM's DMET-SQD and Google's Quantum Echoes, demonstrated chemical accuracy and significant speedups in molecular simulations. These advances were driven by improvements in quantum error correction, a shift toward solving real-world problems, interdisciplinary collaboration, and innovative noise-aware algorithms. By 2026, hybrid workflows enabled simulations of complex molecules with up to 16 qubits, achieving reliable results despite persistent hardware and talent challenges. Strategic efforts, including IBM's quantum-centric supercomputing architecture, government investments, and expanded cloud access, are accelerating progress. Near-term milestones focus on error mitigation and AI integration, paving the way for fault-tolerant systems and transformative impacts on drug discovery and materials science by the 2030s.